E25Bio

E25Bio develops Rapid Diagnostic Tests for fever syndromes which account for over 1 billion episodes annually and are one of the most common reasons to seek care worldwide . The company is working on rapid diagnosis of diseases such as dengue, zika and COVID-19. E25VBio’s diagnostic tests use nanoparticle technology to capture virus or viral proteins that are secreted in the body based on technology developed by Irene Bosch and Lee Gehrke, the Hermann von Helmholtz Professor of Health Sciences and Technology at MIT.

The company’s COVID-19 test is similar to a pregnancy test and it has received $2 million from Khosla Ventures which will fund research and development, clinical studies and scaling launch of diagnostic tests once FDA Emergency Use Approval (EUA) approval is received.